Wellington Management Group LLP Has $3.75 Million Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

Wellington Management Group LLP increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 22.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 389,706 shares of the company's stock after buying an additional 72,432 shares during the quarter. Wellington Management Group LLP owned about 0.26% of MiMedx Group worth $3,749,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MDXG. Invesco Ltd. lifted its position in shares of MiMedx Group by 2.2% during the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company's stock valued at $544,000 after acquiring an additional 1,226 shares during the period. Tower Research Capital LLC TRC raised its stake in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares in the last quarter. IMG Wealth Management Inc. bought a new stake in MiMedx Group during the fourth quarter worth about $28,000. Bank of New York Mellon Corp lifted its position in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after purchasing an additional 3,300 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new stake in MiMedx Group during the fourth quarter worth about $35,000. Institutional investors own 79.15% of the company's stock.

MiMedx Group Price Performance

Shares of MiMedx Group stock traded up $0.15 during trading on Friday, reaching $6.49. 372,385 shares of the company's stock were exchanged, compared to its average volume of 688,572. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a market cap of $958.59 million, a P/E ratio of 11.80 and a beta of 1.82. The firm's 50-day moving average price is $6.83 and its 200 day moving average price is $8.03.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

MDXG has been the subject of several analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. Wall Street Zen raised shares of MiMedx Group from a "hold" rating to a "buy" rating in a research note on Friday.

Insider Activity at MiMedx Group

In related news, CEO Joseph H. Capper bought 200,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the transaction, the chief executive officer now directly owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now owns 310,836 shares of the company's stock, valued at $2,452,496.04. This trade represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 141,907 shares of company stock valued at $1,112,580. 1.70% of the stock is owned by insiders.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.